Test ID RAVU Ravulizumab, Serum
Ordering Guidance
To screen test complement abnormalities in the alternative pathway, order RAVUM / Ravulizumab Complement Blockage Monitoring, Serum.
Specimen Required
Patient Preparation: Natalizumab or eculizumab must be discontinued at least 4 weeks prior to testing for ravulizumab quantitation in serum.
Preferred: Red top
Acceptable: Serum gel
Submission Container/Tube: Plastic vial
Specimen Volume: 2.5 mL
Collection Instructions:
1. Draw blood immediately before next scheduled dose.
2. Centrifuge and aliquot serum into a plastic vial within 2 hours of collection.
Useful For
Assessing the response to ravulizumab therapy
Assessing the need for dose escalation
Evaluating the potential for dose de-escalation or discontinuation of therapy in remission states
Monitoring patients who need to be above a certain ravulizumab concentration in order to improve the odds of a clinical response for therapy optimization
This test is not useful as the sole basis for a diagnosis or treatment decisions.
Method Name
Liquid Chromatography-Tandem Mass Spectrometry, High Resolution Accurate Mass (LC-MS/MS HRAM)
Reporting Name
Ravulizumab, SSpecimen Type
SerumSpecimen Minimum Volume
1.1 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 28 days | |
Ambient | 28 days | ||
Frozen | 28 days |
Reference Values
Lower limit of quantitation=5.0 mcg/mL
>175 mcg/mL-Therapeutic concentration for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome
Performing Laboratory

Test Classification
This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
80299
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
RAVU | Ravulizumab, S | 97184-6 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
609420 | Ravulizumab, S | 97184-6 |
Day(s) Performed
Wednesday
Report Available
3 to 9 daysForms
If not ordering electronically, complete, print, and send a Coagulation Test Request (T753) with the specimen.